378 related articles for article (PubMed ID: 16675962)
21. PPAR dual agonists: are they opening Pandora's Box?
Balakumar P; Rose M; Ganti SS; Krishan P; Singh M
Pharmacol Res; 2007 Aug; 56(2):91-8. PubMed ID: 17428674
[TBL] [Abstract][Full Text] [Related]
22. Combination treatment with pioglitazone and fenofibrate attenuates pioglitazone-mediated acceleration of bone loss in ovariectomized rats.
Samadfam R; Awori M; Bénardeau A; Bauss F; Sebokova E; Wright M; Smith SY
J Endocrinol; 2012 Feb; 212(2):179-86. PubMed ID: 22062085
[TBL] [Abstract][Full Text] [Related]
23. Improved insulin sensitivity after treatment with PPARγ and PPARα ligands is mediated by genetically modulated transcripts.
Rasouli N; Kern PA; Elbein SC; Sharma NK; Das SK
Pharmacogenet Genomics; 2012 Jul; 22(7):484-97. PubMed ID: 22437669
[TBL] [Abstract][Full Text] [Related]
24. Effects of PPARs agonists on cardiac metabolism in littermate and cardiomyocyte-specific PPAR-γ-knockout (CM-PGKO) mice.
Barbieri M; Di Filippo C; Esposito A; Marfella R; Rizzo MR; D'Amico M; Ferraraccio F; Di Ronza C; Duan SZ; Mortensen RM; Rossi F; Paolisso G
PLoS One; 2012; 7(4):e35999. PubMed ID: 22563432
[TBL] [Abstract][Full Text] [Related]
25. Mitochondrial dysfunction by synthetic ligands of peroxisome proliferator activated receptors (PPARs).
Scatena R; Martorana GE; Bottoni P; Giardina B
IUBMB Life; 2004 Aug; 56(8):477-82. PubMed ID: 15545227
[TBL] [Abstract][Full Text] [Related]
26. Multitargeted bioactive ligands for PPARs discovered in the last decade.
Zhang J; Liu X; Xie XB; Cheng XC; Wang RL
Chem Biol Drug Des; 2016 Nov; 88(5):635-663. PubMed ID: 27317624
[TBL] [Abstract][Full Text] [Related]
27. Effects of peroxisome proliferator activated receptors (PPAR)-γ and -α agonists on cochlear protection from oxidative stress.
Sekulic-Jablanovic M; Petkovic V; Wright MB; Kucharava K; Huerzeler N; Levano S; Brand Y; Leitmeyer K; Glutz A; Bausch A; Bodmer D
PLoS One; 2017; 12(11):e0188596. PubMed ID: 29182629
[TBL] [Abstract][Full Text] [Related]
28. Effects of combined PPARgamma and PPARalpha agonist therapy on reverse cholesterol transport in the Zucker diabetic fatty rat.
Tanabe J; Tamasawa N; Yamashita M; Matsuki K; Murakami H; Matsui J; Sugimoto K; Yasujima M; Suda T
Diabetes Obes Metab; 2008 Sep; 10(9):772-9. PubMed ID: 17970759
[TBL] [Abstract][Full Text] [Related]
29. Human sebum requires de novo lipogenesis, which is increased in acne vulgaris and suppressed by acetyl-CoA carboxylase inhibition.
Esler WP; Tesz GJ; Hellerstein MK; Beysen C; Sivamani R; Turner SM; Watkins SM; Amor PA; Carvajal-Gonzalez S; Geoly FJ; Biddle KE; Purkal JJ; Fitch M; Buckeridge C; Silvia AM; Griffith DA; Gorgoglione M; Hassoun L; Bosanac SS; Vera NB; Rolph TP; Pfefferkorn JA; Sonnenberg GE
Sci Transl Med; 2019 May; 11(492):. PubMed ID: 31092695
[TBL] [Abstract][Full Text] [Related]
30. Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonists on 11beta-hydroxysteroid dehydrogenase type 1 in subcutaneous adipose tissue in men.
Wake DJ; Stimson RH; Tan GD; Homer NZ; Andrew R; Karpe F; Walker BR
J Clin Endocrinol Metab; 2007 May; 92(5):1848-56. PubMed ID: 17327378
[TBL] [Abstract][Full Text] [Related]
31. Peroxisome-proliferator receptor gamma represses hepatic sex hormone-binding globulin expression.
Selva DM; Hammond GL
Endocrinology; 2009 May; 150(5):2183-9. PubMed ID: 19179433
[TBL] [Abstract][Full Text] [Related]
32. Epigallocatechin-3-gallate suppresses IGF-I-induced lipogenesis and cytokine expression in SZ95 sebocytes.
Im M; Kim SY; Sohn KC; Choi DK; Lee Y; Seo YJ; Kim CD; Hwang YL; Zouboulis CC; Lee JH
J Invest Dermatol; 2012 Dec; 132(12):2700-8. PubMed ID: 22763784
[TBL] [Abstract][Full Text] [Related]
33. PPARalpha agonists stimulate progastrin production in human colorectal carcinoma cells.
Lachal S; Ford J; Shulkes A; Baldwin GS
Regul Pept; 2004 Aug; 120(1-3):243-51. PubMed ID: 15177943
[TBL] [Abstract][Full Text] [Related]
34. Ameliorative effect of combination of fenofibrate and rosiglitazone in pressure overload-induced cardiac hypertrophy in rats.
Rose M; Balakumar P; Singh M
Pharmacology; 2007; 80(2-3):177-84. PubMed ID: 17570955
[TBL] [Abstract][Full Text] [Related]
35. Peroxisome proliferator-activated receptor activity is involved in the osteoblastic differentiation regulated by bone morphogenetic proteins and tumor necrosis factor-α.
Takano M; Otsuka F; Matsumoto Y; Inagaki K; Takeda M; Nakamura E; Tsukamoto N; Miyoshi T; Sada KE; Makino H
Mol Cell Endocrinol; 2012 Jan; 348(1):224-32. PubMed ID: 21888945
[TBL] [Abstract][Full Text] [Related]
36. PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia.
Hennuyer N; Tailleux A; Torpier G; Mezdour H; Fruchart JC; Staels B; Fiévet C
Arterioscler Thromb Vasc Biol; 2005 Sep; 25(9):1897-902. PubMed ID: 15994444
[TBL] [Abstract][Full Text] [Related]
37. Peroxisome proliferator activated receptor (PPAR)alpha agonists inhibit hypertrophy of neonatal rat cardiac myocytes.
Liang F; Wang F; Zhang S; Gardner DG
Endocrinology; 2003 Sep; 144(9):4187-94. PubMed ID: 12933694
[TBL] [Abstract][Full Text] [Related]
38. Switching subtype-selectivity: Fragment replacement strategy affords novel class of peroxisome proliferator-activated receptor α/δ (PPARα/δ) dual agonists.
Shioi R; Okazaki S; Noguchi-Yachide T; Ishikawa M; Makishima M; Hashimoto Y; Yamaguchi T
Bioorg Med Chem Lett; 2017 Jul; 27(14):3131-3134. PubMed ID: 28539218
[TBL] [Abstract][Full Text] [Related]
39. Identification of novel multitargeted PPARα/γ/δ pan agonists by core hopping of rosiglitazone.
Wang XJ; Zhang J; Wang SQ; Xu WR; Cheng XC; Wang RL
Drug Des Devel Ther; 2014; 8():2255-62. PubMed ID: 25422585
[TBL] [Abstract][Full Text] [Related]
40. Involvement of PPARgamma in oxidative stress-mediated prostaglandin E(2) production in SZ95 human sebaceous gland cells.
Zhang Q; Seltmann H; Zouboulis CC; Konger RL
J Invest Dermatol; 2006 Jan; 126(1):42-8. PubMed ID: 16417216
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
